Trial Profile
TOLERANCE OF DOLUTEGRAVIR VERSUS RALTEGRAVIR COMBINED WITH TENOFOVIR DISOPROXIL AND EMTRICITABINE OR LAMIVUDINE AS POSTEXPOSURE PROPHYLAXIS AGAINST HIV INFECTION
Status:
Planning
Phase of Trial:
Phase IV
Latest Information Update: 01 Aug 2021
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary) ; Raltegravir (Primary) ; Emtricitabine; Lamivudine; Tenofovir disoproxil fumarate
- Indications HIV infections
- Focus Adverse reactions
- Acronyms DoRa
- 21 Apr 2018 Status changed from not yet recruiting to planning.
- 17 Apr 2018 New trial record